Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.44 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.44 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.41 |
| ▸ | MVD | P53602 | 3/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18798612 | 1.00 | BTN3A1 (0.44) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL260134 | 1.00 | BTN3A1 (0.44) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL23845594 | 1.00 | BTN3A1 (0.44) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL10880174 | 0.98 | BTN3A1 (0.46) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL8829466 | 0.96 | BTN3A1 (0.47) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL10878442 | 0.94 | BTN3A1 (0.48) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL10880122 | 0.92 | ITPR3 (0.50) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL18798611 | 0.92 | ITPR3 (0.50) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL18798606 | 0.92 | ITPR3 (0.50) | BTN3A1ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL8169756 | 0.88 | ITPR3 (0.53) | BTN3A1ITPR3ITPR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254591-A2 | INHIBITION AND TREATMENT OF GASTROINTESTINAL BIOFILMS | Prothera, Inc. (US) | 2010-12-01 | — | — | EP | claimed |
| WO-2009100456-A2 | INHIBITION AND TREATMENT OF GASTROINTESTINAL BIOFILMS | PROTHERA, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-20230010193-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-12 | — | — | US | disclosed |
| US-11396677-B2 | Chemical methods for producing tagged nucleotides | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3122759-B1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | UNIV COLUMBIA (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-106715453-B | Chemical process for producing tagged nucleotides | 哥伦比亚大学董事会 | 2021-04-30 | — | — | CN | disclosed |
| US-20190276887-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-09-12 | — | — | US | disclosed |
| US-10240195-B2 | Chemical methods for producing tagged nucleotides | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-26 | — | — | US | disclosed |
| CN-108350017-A | Polypeptide-labeled nucleotides and their use in nucleic acid sequencing by nanopore detection | 豪夫迈·罗氏有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3122759-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | The Trustees of Columbia University in the City of New York (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20150368710-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2015148402-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368710-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | NT5C3B, NCL, NUDT1 | BTN3A1 4206/4885ITPR3 2053/4885ITPR1 1184/4885 |
| US-20230010193-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | NT5C3B, NCL, NUDT1 | BTN3A1 4206/4885ITPR3 2053/4885ITPR1 1184/4885 |
| US-11396677-B2 | Chemical methods for producing tagged nucleotides | NT5C3B, NCL, NUDT1 | BTN3A1 4206/4885ITPR3 2053/4885ITPR1 1184/4885 |
| US-20190276887-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | NT5C3B, NCL, NUDT1 | BTN3A1 4206/4885ITPR3 2053/4885ITPR1 1184/4885 |
| US-10240195-B2 | Chemical methods for producing tagged nucleotides | NT5C3B, NCL, NUDT1 | BTN3A1 4206/4885ITPR3 2053/4885ITPR1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.